- Today's Hot Chat Topics
- Member Benefits
- Manage your personalised Watchlist.
- Set up an online Virtual Portfolio.
- Participate in Share Chat.
- See more trades and director dealings.
- Play the Fantasy Share Trading Game.
Share:
HomeShare PricesShare ChatFinance NewsSharecast NewsRegulatory NewsBlogsLive PricesShares BookshopFinance ToolsMembers
Latest Share Chat
Finance & Stock Market News
Antisoma's executives leave after drug setbacks
Mon, 28th Feb 2011 16:17
LONDON, Feb 28 (Reuters) - The top management of Antisoma stepped down on Monday as the Briti
The company's leukaemia drug candidate AS1413 failed in a final-stage trial in January, delivering a second blow after the failure of a lung cancer drug, its biggest hope, in March 2010. [ID:nLDE70U090}
Chief Executive Glyn Edwards and finance director Eric Dodd had both resigned, the company said, although Dodd will continue to advises the firm on strategic options, which includes a sale of the company.
Shares in Antisoma, once one of Britain's brightest biotech hopes, were valued at more than 200 pence in March 2000 when the sector was riding high.
The shares were trading at 3 pence at 1554 GMT.
(Reporting by Paul Sandle) Keywords: ANTISOMA/
(paul.sandle@reuters.com; +44 20 7542-6843; Reuters Messaging: paul.sandle.reuters.com@reuters.net)
COPYRIGHT
Copyright Thomson Reuters 2011. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
sh cancer specialist cut its operations following the failure of its two leading drug candidates.
The company's leukaemia drug candidate AS1413 failed in a final-stage trial in January, delivering a second blow after the failure of a lung cancer drug, its biggest hope, in March 2010. [ID:nLDE70U090}
Chief Executive Glyn Edwards and finance director Eric Dodd had both resigned, the company said, although Dodd will continue to advises the firm on strategic options, which includes a sale of the company.
Shares in Antisoma, once one of Britain's brightest biotech hopes, were valued at more than 200 pence in March 2000 when the sector was riding high.
The shares were trading at 3 pence at 1554 GMT.
(Reporting by Paul Sandle) Keywords: ANTISOMA/
(paul.sandle@reuters.com; +44 20 7542-6843; Reuters Messaging: paul.sandle.reuters.com@reuters.net)
COPYRIGHT
Copyright Thomson Reuters 2011. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
